Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 24, 2020
Daily News
November 24, 2020
- Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake
November 24, 2020
- Takeda’s ALK Med, 1st Male Indication for HPV Vaccine, Lynparza’s Pancreatic Cancer Use Up for PAFSC Review on Dec. 4
November 24, 2020
- 5-Year Cancer Survival Rate at 68.6%, Largely Unchanged: NCC
November 24, 2020
- 1st Humira Biosimilar to Join NHI Price List on Nov. 25
November 24, 2020
- Takeda Launches Zejula, 2nd PARP Inhibitor in Japan
November 24, 2020
- MHLW to Evaluate Suspected Adverse Reactions to COVID-19 Vaccines More Frequently than Usual: Minister
November 24, 2020
- Govt Won't Disclose Plans for Excess COVID-19 Vaccines: Health Minister
November 24, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…